Daiichi Sankyo

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

Filing due later this year. AstraZeneca has made a big bet on a HER2-targeted antibody-drug conjugate developed by Daiichi Sankyo as it tries to add another pillar to its ... Daiichi Sankyo has said that means its drug can carry a greater cytotoxic

Daiichi Sankyo starts mirogabalin trial in spinal injury pain

The challenge for Daiichi Sankyo with mirogabalin will be positioning it as a realistic alternative to pregabalin when Lyrica generics hit the market. ... Like the original Lyrica formulation Daiichi Sankyo’s drug is dosed twice-daily.

Astellas, Catalyst approvals set up record year for FDA approvals

Others are however moving through the late-stage pipeline, including Daiichi Sankyo’s quizartinib and Arog Pharma’s crenolanib.

The Healthcare Partnership is launched

The company is headed by founder Duane Lacey (pictured), who has over 20 years’ experience within the industry having served in various roles for companies including AstraZeneca, Daiichi-Sankyo and Alliance

Roche preps new Kadcyla filings after phase 3 trial win

Meanwhile, moving Kadcyla up the treatment pathway should help keep the ADC – currently the smallest product of the three – ahead of emerging rivals, such as  Daiichi-Sankyo’s ADC trastuzumab deruxtecan

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]